Associated Papers
MET amplification correlates with poor prognosis and immunotherapy response as a subtype of melanoma: a multicenter retrospective study.
Cai X et al.
Bmc Cancer, 2024
39528978 (PubMed )
Supplement: 12885_2024_13163_MOESM1_ESM.xlsx › SNVs
Targeted sequencing of localized acral melanoma in Korean patients identified recurrent CCND1 amplification.
Kim YS et al.
International Journal of Dermatology, 2022
Rare c-KIT c.1926delA and c.1936T>G Mutations in Exon 13 Define Imatinib Resistance in Gastrointestinal Stromal Tumors and Melanoma Patients: Case Reports and Cell Experiments.
Yan C et al.
Frontiers in Molecular Biosciences, 2022
Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.
Millán-Esteban D et al.
European Journal of Dermatology : Ejd, 2021
KIT mutations and CD117 overexpression are markers of better progression-free survival in vulvar melanomas.
Dias-Santagata D et al.
The British Journal of Dermatology, 2017
Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I.
Orlova KV et al.
Case Reports in Oncology, 0
31043947 (PubMed )
Supplement: cro-0012-0109-s01.pdf
Select a paper to view details